Recent Jobs

  • Senior Project Manager

    Regulatory Professionals
    Europe, Switzerland, Basel City
    • CONTRACT
  • Senior Regulatory Operations Specialist

    Regulatory Professionals
    USA, California
    • FULL TIME
  • Medical Information Associate: Norwegian speaking

    Regulatory Professionals
    Surrey, UK
    • CONTRACT
  • Regulatory Associate Director

    Regulatory Professionals
    Europe, Switzerland
    • FULL TIME
Load more listings

Make your job search easier

Create a candidate account to save jobs for later and have the latest roles and career advice emailed to you.

Register for Job Alerts

Want to see how you compare to the rest of the industry?

Enter your details to receive a complimentary copy of our salary guide delivered to your door.

Life Science Salary Guide

Create an Account

Complete your online profile and make it easier to apply for roles on the move.

Register your Details

Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.

Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.

Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.

The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.

Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.

To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:

•    Regulatory Medical Devices
•    Regulatory Clinical
•    Regulatory CMC
•    Regulatory Submissions and Publishing
•    Regulatory Writing
•    Lifecycle Management

Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.

+44 (0)118 9522 797

Contact us today to find out how we can progress your career to the next level

Latest News

lung xray

Novartis gain EU approval for SMA gene therapy

AveXis, Novartis’ gene therapy division, announced that it has been given European approval for Zolgensma, (onasemnogene abeparvovec), the only gene therapy for spinal muscular atrophy (SMA). Specifically, the European Commission has granted conditional approval for Zolgensma for the treatment of patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical

Continue Reading

NICE give final guidance approving Pfizer’s lung cancer treatment

NICE has published guidance recommending the use of Pfizer’s Lorviqua for a certain form of lung cancer on the NHS. The drug has been recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after: alectinib or ceritinib as the

Continue Reading